pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 17, 26
Argenx jumps on Phase 3 data for blockbuster Vyvgart
biopharma dive
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
endpoints
Aug 17, 26
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
Aug 17, 26
Slate, Fulcrum to combine in reverse merger
biopharma dive
Aug 17, 26
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
Aug 17, 26
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 17, 26
Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
endpoints
Aug 17, 26
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
Aug 17, 26
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 14, 26
Biogen's monoclonal antibody felzartamab wins first global approval in China
endpoints
Aug 14, 26
STAT+: PBMs agree to display TrumpRx drug prices
stat
Aug 14, 26
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
endpoints
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
Aug 14, 26
Biotech initiatives pick up as more regions race to become hubs
biopharma dive
Aug 13, 26
STAT+: Eli Lilly targets booming black market for retatrutide
stat
Aug 13, 26
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 13, 26
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
Aug 13, 26
Behind the bell: Gearing up to go public
biospace
Aug 13, 26
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China
raps
Aug 12, 26
STAT+: Cancer patients face longer wait times to begin treatment, according to new study
stat
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 12, 26
STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
stat
← prev
page 16 of 27
next →